Evidence map›Paper›PMID 35896717›Full record

ReviewInternational journal of impotence research2023

News and future perspectives of non-surgical treatments for erectile dysfunction.

Celeste Manfredi, Fabio Castiglione, Mikkel Fode, Michal Lew-Starowicz, Javier Romero-Otero, Carlo Bettocchi, Giovanni Corona, ESSM Scientific Collaboration and Partnership (ESCAP)

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in International journal of impotence research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Celeste ManfrediUrology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy. manfredi.celeste@gmail.com.ORCID http://orcid.org/0000-0002-9706-8516
Fabio CastiglioneDepartment of Urology, University College London Hospitals NHS Trust, London, UK.ORCID http://orcid.org/0000-0001-8046-1963
Mikkel FodeDepartment of Urology, Copenhagen University Hospital-Herlev and Gentofte Hospital, Herlev, Denmark.ORCID http://orcid.org/0000-0002-8963-4581
Michal Lew-StarowiczDepartment of Psychiatry, Centre of Postgraduate Medical Education, Warsaw, Poland.
Javier Romero-OteroROC Clinic, Madrid, Spain.ORCID http://orcid.org/0000-0002-0666-5105
Carlo BettocchiDepartment of Urology, University of Foggia, Foggia, Italy.ORCID http://orcid.org/0000-0002-1152-3005
Giovanni CoronaEndocrinology Unit, Medical Department, Maggiore-Bellaria Hospital, Bologna, Italy.ORCID http://orcid.org/0000-0002-9894-2885
ESSM Scientific Collaboration and Partnership (ESCAP)
HM Hospitales · ESOspedale Bellaria · ITPostgraduate School of Molecular Medicine · PLUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Copenhagen · DKUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The significant discontinuation rate of available therapies and the paucity of curative options promoted the research on potential novel treatments suitable for erectile dysfunction patients. The aim of this study was to provide a summary of available evidence regarding the news and future perspectives related to the non-surgical treatment of erectile dysfunction. A narrative review of the literature was performed. A comprehensive search in the MEDLINE, Embase, and Scopus databases was done. Papers in English-language, published until April 2022, were included. No chronological restriction was applied. Retrospective and prospective clinical studies, as well as meta-analyses, were considered. Oro-dispersible formulations of phosphodiesterase type 5 inhibitors are particularly indicated in patients who have difficulty in swallowing solid dosage form; in addition, they constitute a discrete route of administration not requiring water. Low-intensity extracorporeal shock wave therapy is indicated in mild vasculogenic erectile dysfunction and in patients with vasculogenic erectile dysfunction poorly responsive to phosphodiesterase type 5 inhibitors. Stem cell therapy, platelet-rich plasma injections, and gene therapy seem promising regenerative treatments for selected patients with erectile dysfunction. Novel oral formulations of drugs commonly used in erectile dysfunction patients have recently become part of standard clinical practice. Regenerative treatments have been emerging in recent years and could become routine curative options in the near future. Further well-designed randomized controlled trials are needed to provide conclusive evidence on this topic and guide appropriate recommendations.

Indexed as

Erectile DysfunctionHumansMalePhosphodiesterase 5 InhibitorsProspective StudiesRetrospective StudiesPhosphodiesterase 5 Inhibitors

Identifiers

PMID35896717
OpenAlexW4288725094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.